Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Neurocrine Biosciences — Merger or Acquisition (April 2026)
12 slides from Neurocrine Biosciences's merger presentation, Apr 6, 2026
Slide 1: Neurocrine Biosciences to Acquire Soleno Therapeutics
Neurocrine Biosciences to Acquire Soleno Therapeutics April 6, 2026 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of each of Soleno and Neurocrine, including statements relating to the ability to complete and the timing of completion of the t
Slide 3: Additional Information About the Acquisition and Where to Find It
Additional Information About the Acquisition and Where to Find It The tender offer for all of the outstanding shares of Soleno described in this communication has not yet commenced. This communication is for informational purposes only, is not a recommendation and is neither an offer to purchase nor
Slide 4: Acquisition of Soleno: Strategic and Financial Fit Positions Neurocrine to Deliver Sustained Growth and Value
Acquisition of Soleno: Strategic and Financial Fit Positions Neurocrine to Deliver Sustained Growth and Value Shared Focus on Rare Accelerates Growth and Positions Neurocrine For Disease and Endocrinology Commercial Diversification Sustained Value Creation Reinforces Neurocrine’s Adds VYKAT XR, the
Slide 5: Financial Overview: Attractive Transaction Terms
Financial Overview: Attractive Transaction Terms • Neurocrine has entered into a definitive agreement to acquire Soleno Therapeutics in an all-cash transaction Purchase Price • Purchase price of $53.00 per share represents a 34% premium to Soleno’s closing price on April 2nd, 2026 and 51% premium to
Slide 6: Soleno Therapeutics: Snapshot
Soleno Therapeutics: Snapshot Company Overview • Commercial-stage rare disease biotechnology company • Lead commercial asset, VYKAT XR granted Breakthrough Therapy Designation by the FDA in April 2024 • VYKAT XR approved by the FDA in March Developing and 2025 as first and only drug to treat Commerc
Slide 7: Prader-Willi Syndrome (PWS) is a Life-Threatening Condition with Significant Patient, Caregiver and Healthcare Burden
Prader-Willi Syndrome (PWS) is a Life-Threatening Condition with Significant Patient, Caregiver and Healthcare Burden Prader-Willi Syndrome (PWS) & Hyperphagia Burden on Patients, Caregivers & Healthcare Systems PWS Occurs spontaneously in ~1 in 15,0001 births Disruption – Behaviors can be both food
Slide 8: VYKAT XR – Changing What It Means to Live with PWS
VYKAT XR – Changing What It Means to Live with PWS FIRST-IN-CLASS VYKAT XR is a first-in-class treatment for hyperphagia in patients with PWS 4 years and older ROBUST DATA Clinical program demonstrated ability to significantly reduce hyperphagia and impact other PWS-related symptoms and co-morbiditi
Slide 9: Acquisition Opportunity Meaningfully Advances Efforts to Enhance Revenue Growth and Diversification
Acquisition Opportunity Meaningfully Advances Efforts to Enhance Revenue Growth and Diversification Increases Neurocrine’s Diversifies Neurocrine’s Leverages Neurocrine’s Topline Growth Revenue Base Existing Expertise ✓ Established rare $92 endocrinology leadership and reputation $66 ✓ Highly specia
Slide 10: Neurocrine Is Well-Positioned to Drive Sustainable Growth and Value
Neurocrine Is Well-Positioned to Drive Sustainable Growth and Value COMMERCIAL RESEARCH & DEVELOPMENT STRONG FINANCIAL POSITION • Neurology *,1 TARDIVE DYSKINESIA & • Psychiatry Therapeutic Area $2.7 - $2.8 Billion Net Sales HUNTINGTON’S DISEASE CHOREA • Endocrinology Diversification 2026 INGREZZA A
Slide 11: Acquisition of Soleno Will Strengthen Leadership in Endocrinology and Rare Disease
Acquisition of Soleno Will Strengthen Leadership in Endocrinology and Rare Disease1 Expands and Strengthens Neurocrine’s Leadership in Rare Disease and Endocrinology Adds VYKAT XR, the First and Only Approved Medicine for the Treatment of Hyperphagia in PWS Immediately Accelerates Neurocrine’s Reven
Slide 12: Q&A
Q&A Kyle Matt Eric Sanjay Samir Gano, Ph.D. Abernethy Benevich Keswani, M.D. Siddhanti Chief Executive Officer Chief Financial Officer Chief Commercial Officer Chief Medical Officer Vice President, Business Development & Strategy 12
Neurocrine Biosciences — Merger or Acquisition (April 2026) on 6ix